nach oben

Medical Oncology

Erschienen in:

01.07.2023 | Perspectives in Oncology

Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy

verfasst von: Simran Deep Kaur, Aman Deep Singh, Deepak N. Kapoor

Erschienen in: Medical Oncology | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Viruses are being researched as cutting-edge therapeutic agents in cancer due to their selective oncolytic action against malignancies. Immuno-oncolytic viruses are a potential category of anticancer treatments because they have natural features that allow viruses to efficiently infect, replicate, and destroy cancer cells. Oncolytic viruses may be genetically modified; engineers can use them as a platform to develop additional therapy modalities that overcome the limitations of current treatment approaches. In recent years, researchers have made great strides in the understanding relationship between cancer and the immune system. An increasing corpus of research is functioning on the immunomodulatory functions of oncolytic virus (OVs). Several clinical studies are currently underway to determine the efficacy of these immuno-oncolytic viruses. These studies are exploring the design of these platforms to elicit the desired immune response and to supplement the available immunotherapeutic modalities to render immune-resistant malignancies amenable to treatment. This review will discuss current research and clinical developments on Vaxinia immuno-oncolytic virus.

Cancer in 2022—CPR22. (n.d.). Cancer Progress Report., https://cancerprogressreport.aacr.org/progress/cpr22-contents/cpr22-cancer-in-2022/. Accessed 30 April 2023

Cancer. (n.d.)., https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 23 Aug 2022

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–89. https://doi.org/10.1002/ijc.33588.CrossRef

Lauer UM, Beil J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol. 2022;18(24):2713–32. https://doi.org/10.2217/fon-2022-0440.CrossRef

Kayode AA, Eya IE, Kayode OT. A short review on cancer therapeutics. Phys Sci Rev. 2022. https://doi.org/10.1515/psr-2021-0169.CrossRef

Nenclares P, Harrington KJ. The biology of cancer. Medicine. 2020;48(2):67–72. https://doi.org/10.1016/j.mpmed.2019.11.001.CrossRef

Cattley RC, Radinsky BR. Cancer therapeutics: understanding the mechanism of action. Toxicol Pathol. 2004;32(1_suppl):116–21. https://doi.org/10.1080/01926230490426507.CrossRefPubMed

Vesely MD, Schreiber RD. Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy: tumor antigens and cancer immunoediting. Ann N Y Acad Sci. 2013;1284(1):1–5. https://doi.org/10.1111/nyas.12105.CrossRefPubMedPubMedCentral

Gubin MM, Vesely MD. Cancer immunoediting in the era of immuno-oncology. Clin Cancer Res. 2022. https://doi.org/10.1158/1078-0432.CCR-21-1804.CrossRefPubMedPubMedCentral

10.

Wilczyński JR, Nowak M. Cancer Immunoediting Elimination, Equilibrium, and Immune Escape in Solid Tumors. In: Klink M, Szulc-Kielbik I, editors. Interaction of Immune and Cancer Cells, vol. 113. Cham: Springer International Publishing; 2022. p. 1–57. https://doi.org/10.1007/978-3-030-91311-3_1.CrossRef

11.

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59. https://doi.org/10.1186/s12964-020-0530-4.CrossRefPubMedPubMedCentral

12.

Atsou K, Khou S, Anjuère F, Braud VM, Goudon T. Analysis of the equilibrium phase in immune-controlled tumors provides hints for designing better strategies for cancer treatment. Front Oncol. 2022;12:878827. https://doi.org/10.3389/fonc.2022.878827.CrossRefPubMedPubMedCentral

13.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8. https://doi.org/10.1038/ni1102-991.CrossRefPubMed

14.

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48. https://doi.org/10.1016/j.immuni.2004.07.017.CrossRefPubMed

15.

Whiteside T. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16(1):3–15. https://doi.org/10.1016/j.semcancer.2005.07.008.CrossRefPubMed

16.

Printezi MI, Kilgallen AB, Bond MJG, Štibler U, Putker M, Teske AJ, Cramer MJ, Punt CJA, Sluijter JPG, Huitema ADR, May AM, van Laake LW. Toxicity and efficacy of chronomodulated chemotherapy: a systematic review. Lancet Oncol. 2022;23(3):e129–43. https://doi.org/10.1016/S1470-2045(21)00639-2.CrossRefPubMed

17.

Alfarouk KO, Stock C-M, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AHH, Mohammed OY, Elhassan GO, Harguindey S, Reshkin SJ, Ibrahim ME, Rauch C. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15(1):71. https://doi.org/10.1186/s12935-015-0221-1.CrossRefPubMedPubMedCentral

18.

Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N. Therapeutic Efficacy of oncolytic viruses in fighting cancer: recent advances and perspective. Oxid Med Cell Longev. 2022;2022:1–14. https://doi.org/10.1155/2022/3142306.CrossRef

19.

Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18(8):498–513. https://doi.org/10.1038/s41577-018-0014-6.CrossRefPubMed

20.

de Graaf JF, de Vor L, Fouchier RAM, van den Hoogen BG. Armed oncolytic viruses: a kick-start for anti-tumor immunity. Cytokine Growth Factor Rev. 2018;41:28–39. https://doi.org/10.1016/j.cytogfr.2018.03.006.CrossRefPubMedPubMedCentral

21.

Yuan Y, Zhang J, Kessler J, Rand J, Modi B, Chaurasiya S, Murga M, Tang A, Martinez N, Meisen H, Yamauchi D, Yost SE, Chong LMO, Seiz A, Nixon B, Ede N, Waisman JR, Stewart DB, Mortimer JE, Fong Y. Phase I study of intratumoral administration of CF33-HNIS-antiPDL1 in patients with metastatic triple negative breast cancer. J Clin Oncol. 2022;40(16_suppl):e13070–e13070. https://doi.org/10.1200/JCO.2022.40.16_suppl.e13070.CrossRef

22.

Imugene (ASX: IMU). (n.d.). https://www.imugene.com/. Accessed 23 Aug 2022

23.

Greseth MD, Traktman P. The life cycle of the vaccinia virus genome. Ann Rev Virol. 2022. https://doi.org/10.1146/annurev-virology-091919-104752.CrossRef

24.

Zhang Z, Dong L, Zhao C, Zheng P, Zhang X, Xu J. Vaccinia virus-based vector against infectious diseases and tumors. Hum Vaccin Immunother. 2021;17(6):1578–85. https://doi.org/10.1080/21645515.2020.1840887.CrossRefPubMedPubMedCentral

25.

Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci. 1982;79(23):7415–9. https://doi.org/10.1073/pnas.79.23.7415.CrossRefPubMedPubMedCentral

26.

Woo Y, Zhang Z, Yang A, Chaurasiya S, Park AK, Lu J, Kim S-I, Warner SG, Von Hoff D, Fong Y. Novel chimeric immuno-oncolytic virus CF33-hNIS-antiPDL1 for the treatment of pancreatic cancer. J Am Coll Surg. 2020;230(4):709–17. https://doi.org/10.1016/j.jamcollsurg.2019.12.027.CrossRefPubMedPubMedCentral

27.

Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-γ: its role in promoting cancer immunoevasion. Int J Mol Sci. 2017;19(1):89. https://doi.org/10.3390/ijms19010089.CrossRefPubMedPubMedCentral

28.

Schirrmacher V. Molecular Mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic newcastle disease virus. Biomedicines. 2022;10(3):562. https://doi.org/10.3390/biomedicines10030562.CrossRefPubMedPubMedCentral

29.

Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH. A Review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(12):87–97. https://doi.org/10.3747/co.27.5223.CrossRef

30.

Davola ME, Mossman KL. Oncolytic viruses: how “lytic” must they be for therapeutic efficacy. OncoImmunology. 2019;8(6):e1581528. https://doi.org/10.1080/2162402X.2019.1596006.CrossRefPubMedPubMedCentral

31.

Rojas-Domínguez A, Arroyo-Duarte R, Rincón-Vieyra F, Alvarado-Mentado M. Modeling cancer immunoediting in tumor microenvironment with system characterization through the ising-model Hamiltonian. BMC Bioinform. 2022;23(1):200. https://doi.org/10.1186/s12859-022-04731-w.CrossRef

32.

Nirmal AJ, Maliga Z, Vallius T, Quattrochi B, Chen AA, Jacobson CA, Pelletier RJ, Yapp C, Arias-Camison R, Chen Y-A, Lian CG, Murphy GF, Santagata S, Sorger PK. The Spatial landscape of progression and immunoediting in primary melanoma at single-cell resolution. Cancer Discov. 2022;12(6):1518–41. https://doi.org/10.1158/2159-8290.CD-21-1357.CrossRefPubMedPubMedCentral

33.

Christie JD, Chiocca EA. Treat and repeat: oncolytic virus therapy for brain cancer. Nat Med. 2022;28(8):1540–2. https://doi.org/10.1038/s41591-022-01901-4.CrossRefPubMed

34.

Chen L, Zhou C, Chen Q, Shang J, Liu Z, Guo Y, Li C, Wang H, Ye Q, Li X, Zu S, Li F, Xia Q, Zhou T, Li A, Wang C, Chen Y, Wu A, Qin C, Man J. Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma. Mol Ther—Oncolytics. 2022;24:522–34. https://doi.org/10.1016/j.omto.2022.01.011.CrossRefPubMedPubMedCentral

35.

Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559–67. https://doi.org/10.1038/nrc3770.CrossRefPubMed

36.

Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008;8(10):1581–8. https://doi.org/10.1586/14737140.8.10.1581.CrossRefPubMedPubMedCentral

37.

Tang C, Li L, Mo T, Na J, Qian Z, Fan D, Sun X, Yao M, Pan L, Huang Y, Zhong L. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical. Clin Transl Oncol. 2022;24(9):1682–701. https://doi.org/10.1007/s12094-022-02830-x.CrossRefPubMedPubMedCentral

38.

Cejalvo JM, Falato C, Villanueva L, Tolosa P, González X, Pascal M, Canes J, Gavilá J, Manso L, Pascual T, Prat A, Salvador F. Oncolytic viruses: a new immunotherapeutic approach for breast cancer treatment. Cancer Treat Rev. 2022;106:102392. https://doi.org/10.1016/j.ctrv.2022.102392.CrossRefPubMed

39.

Haseley A, Alvarez-Breckenridge C, Chaudhury A, Kaur B. Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov. 2009;4(1):1–13. https://doi.org/10.2174/157488909787002573.CrossRefPubMedPubMedCentral

40.

Hemminki O, dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 2020;13(1):84. https://doi.org/10.1186/s13045-020-00922-1.CrossRefPubMedPubMedCentral

41.

Garg AD, Dudek-Peric AM, Romano E, Agostinis P. Immunogenic cell death. Int J Dev Biol. 2015;59(1-2–3):131–40. https://doi.org/10.1387/ijdb.150061pa.CrossRefPubMed

42.

Schmidt SV, Nino-Castro AC, Schultze JL. Regulatory dendritic cells: there is more than just immune activation. Front Immunol. 2012. https://doi.org/10.3389/fimmu.2012.00274.CrossRefPubMedPubMedCentral

43.

Couzin-Frankel J. Cancer immunotherapy. Science. 2013;342(6165):1432–3. https://doi.org/10.1126/science.342.6165.1432.CrossRefPubMed

44.

Mostafa A, Meyers D, Thirukkumaran C, Liu P, Gratton K, Spurrell J, Shi Q, Thakur S, Morris D. Oncolytic reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer. Cancers. 2018;10(6):205. https://doi.org/10.3390/cancers10060205.CrossRefPubMedPubMedCentral

45.

Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen C-H, Lou E, Fujisawa S, Eveno C, Belin L, Zanzonico P, Szalay A, Fong Y. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Res Treat. 2014;148(3):489–99. https://doi.org/10.1007/s10549-014-3180-7.CrossRefPubMedPubMedCentral

46.

Mardi A, Shirokova AV, Mohammed RN, Keshavarz A, Zekiy AO, Thangavelu L, Mohamad TAM, Marofi F, Shomali N, Zamani A, Akbari M. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. Cancer Cell Int. 2022;22(1):168. https://doi.org/10.1186/s12935-022-02585-z.CrossRefPubMedPubMedCentral

47.

Nutter Howard FH, Iscaro A, Muthana M (2022) Oncolytic viral particle delivery. In Systemic Drug Delivery Strategies (pp. 211–230). Elsevier, https://doi.org/10.1016/B978-0-323-85781-9.00008-7

48.

Burgess HM, Pourchet A, Hajdu CH, Chiriboga L, Frey AB, Mohr I. Targeting Poxvirus decapping enzymes and mRNA decay to generate an effective oncolytic virus. Mol Ther—Oncolytics. 2018;8:71–81. https://doi.org/10.1016/j.omto.2018.01.001.CrossRefPubMedPubMedCentral

49.

Gal-Ben-Ari S, Barrera I, Ehrlich M, Rosenblum K. PKR: a kinase to remember. Front Mol Neurosci. 2019;11:480. https://doi.org/10.3389/fnmol.2018.00480.CrossRefPubMedPubMedCentral

50.

Ripp J, Hentzen S, Saeed A. Oncolytic viruses as an adjunct to immune checkpoint inhibition. Front Biosci-Landmark. 2022;27(5):151. https://doi.org/10.31083/j.fbl2705151.CrossRef

51.

Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6(1):291. https://doi.org/10.1038/s41392-021-00687-0.CrossRefPubMedPubMedCentral

52.

Sitta J, Claudio PP, Howard CM. Virus-Based Immuno-Oncology Models. Biomedicines. 2022;10(6):1441. https://doi.org/10.3390/biomedicines10061441.CrossRefPubMedPubMedCentral

53.

Ahrends T, Borst J. The opposing roles of CD4⁺ T cells in anti-tumour immunity. Immunology. 2018;154(4):582–92. https://doi.org/10.1111/imm.12941.CrossRefPubMedPubMedCentral

54.

Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J. Immune Conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study. Front Immunol. 2019;10:1848. https://doi.org/10.3389/fimmu.2019.01848.CrossRefPubMedPubMedCentral

55.

Kielbik M, Szulc-Kielbik I, Klink M. Calreticulin—multifunctional chaperone in immunogenic cell death: potential significance as a prognostic biomarker in ovarian cancer patients. Cells. 2021;10(1):130. https://doi.org/10.3390/cells10010130.CrossRefPubMedPubMedCentral

56.

Das K, Belnoue E, Rossi M, Hofer T, Danklmaier S, Nolden T, Schreiber L-M, Angerer K, Kimpel J, Hoegler S, Spiesschaert B, Kenner L, von Laer D, Elbers K, Derouazi M, Wollmann G. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity. Nat Commun. 2021;12(1):5195. https://doi.org/10.1038/s41467-021-25506-6.CrossRefPubMedPubMedCentral

57.

Lemos de Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol Ther—Methods Clin Dev. 2020;17:349–58. https://doi.org/10.1016/j.omtm.2020.01.001.CrossRefPubMedPubMedCentral

58.

O’Leary MP, Warner SG, Kim S-I, Chaurasiya S, Lu J, Choi AH, Park AK, Woo Y, Fong Y, Chen NG. A novel oncolytic chimeric orthopoxvirus encoding luciferase enables real-time view of colorectal cancer cell infection. Mol Ther—Oncolytics. 2018;9:13–21. https://doi.org/10.1016/j.omto.2018.03.001.CrossRefPubMedPubMedCentral

59.

Warner SG, Kim S-I, Chaurasiya S, O’Leary MP, Lu J, Sivanandam V, Woo Y, Chen NG, Fong Y. A novel chimeric poxvirus encoding hnis is tumor-tropic, imageable, and synergistic with radioiodine to sustain colon cancer regression. Mol Ther—Oncolytics. 2019;13:82–92. https://doi.org/10.1016/j.omto.2019.04.001.CrossRefPubMedPubMedCentral

60.

Kim S-I, Park AK, Chaurasiya S, Kang S, Lu J, Yang A, Sivanandam V, Zhang Z, Woo Y, Priceman SJ, Fong Y, Warner SG. Recombinant orthopoxvirus primes colon cancer for checkpoint inhibitor and cross-primes T cells for antitumor and antiviral immunity. Mol Cancer Ther. 2021;20(1):173–82. https://doi.org/10.1158/1535-7163.MCT-20-0405.CrossRefPubMed

61.

O’Leary MP, Choi AH, Kim S-I, Chaurasiya S, Lu J, Park AK, Woo Y, Warner SG, Fong Y, Chen NG. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. J Transl Med. 2018;16(1):110. https://doi.org/10.1186/s12967-018-1483-x.CrossRefPubMedPubMedCentral

62.

Zhang Z, Yang A, Chaurasiya S, Park AK, Lu J, Kim S-I, Warner SG, Yuan Y-C, Liu Z, Han H, Von Hoff D, Fong Y, Woo Y. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Ther. 2021. https://doi.org/10.1038/s41417-021-00350-4.CrossRefPubMedPubMedCentral

63.

Chaurasiya S, Yang A, Kang S, Lu J, Kim S-I, Park AK, Sivanandam V, Zhang Z, Woo Y, Warner SG, Fong Y. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. OncoImmunology. 2020;9(1):1729300. https://doi.org/10.1080/2162402X.2020.1729300.CrossRefPubMedPubMedCentral

64.

Zhang Z, Yang A, Chaurasiya S, Park AK, Kim S-I, Lu J, Olafsen T, Warner SG, Fong Y, Woo Y. PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1. Mol Ther—Oncolytics. 2022;24:331–9. https://doi.org/10.1016/j.omto.2021.12.022.CrossRefPubMed

65.

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer—Full Text View—ClinicalTrials.gov. (n.d.) https://clinicaltrials.gov/ct2/show/NCT05081492.

66.

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination with Pembrolizumab in Adults with Metastatic or Advanced Solid Tumors ClinicalTrials.gov. (n.d.). https://clinicaltrials.gov/ct2/show/NCT05346484. Acccessed 23 Aug 2022,

Titel: Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy
verfasst von: Simran Deep Kaur
Aman Deep Singh
Deepak N. Kapoor
Publikationsdatum: 01.07.2023
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 7/2023
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-02068-9

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2023

Isorhamnetin exerts anti-tumor activity in DEN + CCl4-induced HCC mice

Therapeutic targeting approach on epithelial-mesenchymal plasticity to combat cancer metastasis

Pretreatment of prostate cancer cells with salinomycin and Wnt inhibitor increases the efficacy of cabazitaxel by inducing apoptosis and decreasing cancer stem cells

Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target

Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC)

Implications of IL-21 in solid tumor therapy

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie